We serve Chemical Name:2-Chlorobiphenylene CAS:50558-21-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-Chlorobiphenylene
CAS.NO:50558-21-9
Synonyms:2-chloro-biphenylene;2-Chlorbiphenylen;Biphenylene,2-chloro
Molecular Formula:C12H7Cl
Molecular Weight:186.63700
HS Code:2903999090
Physical and Chemical Properties:
Melting point:65-66ºC
Boiling point:509.7ºC at 760 mmHg
Density:1.32g/cm3
Index of Refraction:1.7
PSA:
Exact Mass:186.02400
LogP:3.98740
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 2-chloro-biphenylene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Biphenylene,2-chloro physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Biphenylene,2-chloro Use and application,2-chloro-biphenylene technical grade,usp/ep/jp grade.
Related News: In addition, a high-standard GMP workshop is under construction and is expected to be put into production within the year. As the capacity bottleneck is broken, the pharmaceutical intermediate business is expected to grow rapidly in the future, providing the company with new growth momentum. 2-Chlorobiphenylene manufacturer The drug substance is an active product that has completed the synthetic route, and the intermediate is a product in one place in the synthetic route. 2-Chlorobiphenylene supplier The foundational patent, which expires in 2034, is owned by MSK and is licensed exclusively to Fate Therapeutics for all human therapeutic uses. 2-Chlorobiphenylene vendor In approving the first new Alzheimer’s drug in nearly 20 years, the U.S. Food and Drug Administration is taking its biggest risk yet with a strategy that allows new therapies onto the market without strong evidence that they work, regulatory and scientific experts say. 2-Chlorobiphenylene factory This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?
